Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Specific IgG2 antibodies toPseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis

Spezifische IgG2 Antikörper von Pseudomonas aeruginosa — Lipid A und Lipopolysaccharide sind frühzeitige Marker einer chronischen Infektion bei Patienten mit Cystischer Fibrose

Summary

The IgG subclass antibody response to the two parts ofPseudomonas aeruginosa lipopolysaccharide; endotoxic lipid A and the O-polysaccharide, were investigated in a retrospective longitudinal study involving 16 patients with cystic fibrosis and chronicP. aeruginosa lung infection. The purpose of the study was to see if any of the IgG subclasses of either specificity could be used as prognostic markers in the development and subsequent course of the lung disease. IgG2 anti-lipid A, IgG3 anti-lipid A, and IgG2 anti-polysaccharide showed a significant positive correlation with deteriorating pulmonary function already before chronicP. aeruginosa lung infection was diagnosed as well as in subsequent years. The findings suggest antigenic exposure of the patient before chronic infection is detected by routine sputum examinations, and further support our previous findings of a critical role of the IgG subclass response in modulating the course of inflammatory lung damage in these patients.

Zusammenfassung

In einer retrospektiven longitudinalen Studie wurde bei 16 Patienten mit zystischer Fibrose und chronischer Lungeninfektion durchPseudomonas aeruginosa die IgG-Subklassen-Antikörperreaktion auf die beiden Anteile desP. aeruginosa-Lipopolysaccharids, das Endotoxin Lipoid A und O-Polysaccharid, untersucht. Dabei sollte geprüft werden, ob sich aus der spezifischen Antikörperantwort einer der IgG-Subklassen prognostische Marker für die Entwicklung und den weiteren Verlauf der Lungenerkrankung ableiten lassen. Eine positive Korrelation mit einer Verschlechterung der Lungenfunktion zeigte sich für anti-Lipoid A-IgG2- und IgG3-und anti-Polysaccharid IgG2-Antikörper schon bevor die chronischeP. aeruginosa-Infektion der Lunge diagnostiziert wurde und auch in den nachfolgenden Jahren. Diese Befunde lassen darauf schließen, daß es schon vor dem Nachweis der chronischen Infektion in Routine-Sputumuntersuchungen zu einer Antigenexposition kommt. Sie bestätigen frühere Studien, in denen wir feststellen konnten, daß die IgG-Subklassen-Reaktion in kritischer Weise den Verlauf der entzündlichen Lungenschädigung bei diesen Patienten mitbestimmt.

This is a preview of subscription content, log in to check access.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

References

  1. 1.

    Pedersen, S. S. Lung infection with alginate-producing, mucoidPseudomonas aeruginosa in cystic fibrosis. APMIS 100 (Suppl. 28) (1992) 7–79.

  2. 2.

    Pressler, T., Pedersen, S. S., Espersen, F., Høiby, N., Koch, C. IgG subclass antibodies toPseudomonas aeruginosa in sera from patients with chronicPs. aeruginosa infection investigated by ELISA. Clin. Exp. Immunol. 81 (1990) 428–434.

  3. 3.

    Moss, R. B., Hsu, Y-P., Lewiston, N. J., Curd, J. G., Milgrom, H., Hart, S., Dyer, B., Larrick, J. W. Association of systemic immune complexes, complement activation, and antibodies toPseudomonas aeruginosa lipopolysaccharide and exotoxin A with mortality in cystic fibrosis. Am. Rev. Respir. Dis. 133 (1986) 648–652.

  4. 4.

    Fomsgaard, A., Dinesen, B., Shand, G. H., Pressler, T., Høiby, N. Antilipopolysaccharide antibodies and differential diagnosis of chronicPseudomonas aeruginosa lung infection in cystic fibrosis. J. Clin. Microbiol. 27 (1989) 1222–1229.

  5. 5.

    Kronborg, G., Fomsgaard, A., Galanos, C., Freudenberg, M. A., Høiby, N. Antibody responses to lipid A, core, and O sugars of thePseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients. J. Clin. Microbiol. 30 (1992) 1848–1855.

  6. 6.

    Kronborg, G., Shand, G. H., Fomsgaard, A., Høiby, N. Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronicPseudomonas aeruginosa lung infection. APMIS 100 (1992) 175–180.

  7. 7.

    Pressler, T., Pandey, J. P., Espersen, F., Pedersen, S. S., Fomsgaard, A., Koch, C., Høiby, N. Immunoglobulin allotypes and IgG sublcass antibody response toPseudomonas aeruginosa antigens in chronically infected cystic fibrosis patients. Clin. Exp. Immunol. 90 (1992) 209–214.

  8. 8.

    Polgar, G., Promadhat, V. Pulmonary function testing in children. Techniques and standards. W. B. Saunders, Philadelphia 1971, 88–107, 178–180.

  9. 9.

    Freudenberg, M. A., Fomsgaard, A., Mitov, I., Galanos, C. ELISA for antibodies to lipid A, lipopolysaccharide and other hydrophobic antigens. Infection 17 (1989) 322–328.

  10. 10.

    Westphal, O., Jann, K. Bacterial lipopolysaccharides: extraction with phenol-water and further applications of the procedure. Methods Carbohydr. Chem. 5 (1965) 83–91.

  11. 11.

    Ojeniyi, B., Høiby, N., Rosdahl, V. T. Prevalence and persistence of polyagglutinablePseudomonas aeruginosa in isolates from cystic fibrosis patients. APMIS 99 (1991) 187–195.

  12. 12.

    Fomsgaard, A., Shand, G. H., Freudenberg, M. A., Galanos, C., Conrad, R. S., Kronborg, G., Høiby, N. Antibodies from chronically infected cystic fibrosis patients react with lipopolysaccharide extracted by new micro-methods from all serotypes ofPseudomonas aeruginosa. APMIS 101 (1993) 101–112.

  13. 13.

    Kronborg, G., Fomsgaard, A., Shand, G. H., Høiby, N. Determination of the components of immune complexes madein vitro with antigens derived fromPseudomonas aeruginosa. J. Immunol. Methods. 122 (1989) 51–57.

  14. 14.

    Kronborg, G., Fomsgaard, A., Shand, G. H., Lanng, S., Hansen, M. B., Pressler, T., Høiby, N. TNF-α and immune complexes in sputum and serum from patients with cystic fibrosis and chronicPseudomonas aeruginosa lung infection. Immunol. & Infect. Dis. 2. (1992) 171–177.

  15. 15.

    Galanos, C., Rietschel, E. T., Lüderitz, O., Westphal, O. Interaction of lipopolysaccharide and lipid A with complement. Eur. J. Biochem. 19 (1971) 143–152.

  16. 16.

    Hancock, R. E., Mutharia, L. C., Chan, L., Darveau, R. P., Speert, D. P., Pier, G. B. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect. Immun. 42 (1983) 170–177.

  17. 17.

    Fomsgaard, A., Conrad, R. S., Galanos, C., Shand, G. H., Høiby, N. Comparative immunochemistry of lipopolysaccharides from typable and polyagglutinablePseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J. Clin. Microbiol. 26 (1988) 821–826.

  18. 18.

    Marget, W. Lipoid A — Antikörpertiter beim Menschen. Infection 15 (1987) 142–145.

  19. 19.

    Pressler, T., Pedersen, S. S., Espersen, F., Høiby, N., Koch, C. IgG subclass antibody responses to alginate fromPseudomonas aeruginosa in patients with cystic fibrosis and chronicP. aeruginosa infection. Ped. Pulm. 14 (1992) 44–51.

  20. 20.

    Ziegler, E. J., Fisher, Jr., C. J., Sprung, C. L., Straube, R. C., Sadoff, J. C., Foulke, G. E., Wortel, C. H., Fink, M. P., Dellinger, R. P., Teng, N. N. H., Allen, I. E., Berger, H. J., Knatterud, G. L., LoBuglio, A. F., Smith, C. R., andthe HA-1A Sepsis Study Group Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, doubleblind, placebo-controlled trial. N. Engl. J. Med. 324 (1991) 429–436.

  21. 21.

    Hornick, D. B., Fick, Jr., R. B. The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. J. Clin. Invest. 86 (1990) 1285–1292.

  22. 22.

    Kronborg, G., Hansen, M. B., Svenson, M. Fomsgaard, A., Høiby, N., Bendtzen, K. Cytokines in sputum and serum from patients with cystic fibrosis and chronicPseudomonas aeruginosa lung infection as markers of destructive inflammation in the lungs. Ped. Pulm 15 (1993) 292–297.

  23. 23.

    Arend, W. P., Joslin, F. G., Massoni, R. J. Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J. Immunol. 134 (1985) 3868–3875.

Download references

Author information

Correspondence to Gitte Kronborg M. D..

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kronborg, G., Pressler, T., Fomsgaard, A. et al. Specific IgG2 antibodies toPseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis. Infection 21, 297–302 (1993). https://doi.org/10.1007/BF01712448

Download citation

Keywords

  • Cystic Fibrosis
  • Lung Infection
  • Specific IgG2
  • Antigenic Exposure
  • Specific IgG2 Antibody